ArticleFrontiers in oncology2022
The epidemic of thyroid cancer in China: Current trends and future prediction.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Apolipoprotein E promotes papillary thyroid carcinoma progression by activating PINK1/Parkin-mediated mitophagy.Translational cancer research · 2026Article
- Artificial intelligence and elastography in diagnostic work-up of thyroid nodules: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- Triglyceride-glucose-Body Mass Index is linked to papillary thyroid carcinoma odds in China: a retrospective study.Frontiers in endocrinology · 2026Article
- Intra- and Inter-Observer Reliability of ChatGPT-4o in Thyroid Nodule Ultrasound Feature Analysis Based on ACR TI-RADS: An Image-Based Study.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- A 6-Year Retrospective Study in Surgery Patients with Thyroid Diseases in Mureș County, Romania, Before and During the COVID-19 Pandemic.Diagnostics (Basel, Switzerland) · 2025Article
- Intelligent prediction of thyroid cancer in China based on GBD data and hospital electronic medical records: disease burden analysis combined with multiple machine learning models.Frontiers in endocrinology · 2025Article
- Review
- Thyroid cancer trends in China and its comparative analysis with G20 countries: Projections for 2020-2040.Journal of global health · 2024Observational
- Impact of fellowship training for specialists on thyroidectomy outcomes of patients with thyroid cancer.Scientific reports · 2024Review
- Prospective role of lusianthridin in attenuating cadmium-induced functional and cellular damage in rat thyroid.Heliyon · 2024Article
- Feasibility and safety of modified en-bloc resection in endoscopic thyroid surgery via bilateral areolar approach - long-term institutional analysis ten years after surgery.Frontiers in endocrinology · 2024Article
- Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.Cancer immunology, immunotherapy : CII · 2023Review
- Overview and countermeasures of cancer burden in China.Science China. Life sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer (TC) is one of the most common cancers in China. The aim of this study was to identify the potential age, period, and cohort effect under the long-term trends in TC incidence and mortality, making projections up to 2030. Methods: Incidence and mortality data on TC were obtained from the Global Burden of Disease Study 2019. The population predictions were obtained from the United Nations World Population Prospects 2019. An age-period-cohort model was used for the analysis. Results: From 1990 to 2019, the net drift (the overall annual percentage change of TC over time adjusted for age groups) of the TC incidence was 5.01% (95% confidence interval [CI]: 4.72%, 5.29%) for men and 1.48% (95% CI: 1.14%, 1.82%) for women. The net drift of TC mortality was 1.64% (95% CI: 1.38%, 1.91%) for men and -2.51% (95% CI: -2.77%, -2.26%) for women. Regarding the incidence of TC, both the period and the cohort relative risks (RRs) in men and women showed an overall increasing trend. As to the mortality rate of TC, both the period and cohort RRs in women showed a monotonic declining trend. The period RRs for men decreased after 2015, but the cohort RRs revealed a fluctuating upward pattern. From 2019 to 2030, the TC incidence was projected to rise by 32.4% in men and 13.1% in women, the mortality declining by 13.0% in men and 17.3% in women. The elderly was projected to have an increasing proportion of TC occurrence and deaths. Conclusions: Over the past 30 years, the incidence rate of TC in China has continually increased, and this trend was projected to continue. Although male mortality has increased in the past, it is expected to decline in the future. The proportion of older people among TC occurrence and death was projected to gradually increase, and the difficulties elderly with TC lrequire more attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.